Table 4.

Summary of published CAR-T therapy in transplant recipients

Baseline Characteristics					Disease Characteristics at Diagnosis					Disease therapy				CAR-T adverse events and outcomes
Series/Pt #	Age	Gender	Organ transplanted, year	Posttransplant immunosuppression	Time from transplant (years)	EBV tumor Status	Pathology	Stage	IPI	1^st-line therapy	Salvage therapy	Bridging Therapy	Immunosuppression management on CAR-T	CRS Grade	ICANS	Other toxicity	Outcome
Krishnamoorthy et al. / Pt 1	54	M	DDKT, 1997; Pancreas, 2010	Tacrolimus, azathioprine, prednison	20	Negative	DLBCL-GCB	4	2	Rituximabalone, R-CHOP	RICE	None	Low dose tacrolimus and prednisone	1	2	AKI, acute pancreatitis, late on set FUO	Transition to hospice w/de at h at day 115 due to refractory PT LD
Krishnamoorthy et al. / Pt 2	54	F	Heart, 1992	Tacrolimus, MMF, prednisone	26	Negative	DLBCL-non GCB	4	3	R-CHOP	R-ICE	Lenalid omide	Switched from tacrolimus to sirolimus	2	3	AKI requiring RRT	Transition to hospice with de at h at day 44 due to persistent lower GI bleed from refractory PTLD
Krishnamoorthy et al. / pt 3	71	M	DDkt, 2009	Tacrolimus, azathioprine, prednisone	10	Negative	DLBCL-non GCB	4	4	R-CHOP	R-DHAX, ibrutinib	Gemcitabine and etoposide	Stopped prior	3	4	AKI requiring RRT, As pergillus Pneumonia, VRE bacteremia	Terminally extubated to comfort care, with death at day 15 from with refractory PTLD
Mamlouk et. al./ pt 1	38	M	Kidney	Tacrolimus, MMF, prednisone	10	Negative	DLBC L - GCB	4	3	R-EPOCH	R-GEM-OX	N/A	Stopped tacrolimus and MMF prior, Low dose prednisone	1	No	Allograft rejection @ week +16	CR at 1 month, sustained up to month 7
Mamlouk et. al. / Pt 2	44	M	Kidney	Sirolimus, prednisone	10	Negative	DLBCL-GCB	4	3	R-CHOP	None	N/A	Stopped prior	1	3	Pneumonia, AKI	CR at 1 month, relapsed at 34 weeks
Mamlouk et. al. / Pt 3	41	M	Kidney	Sirolimus, prednisone	7	Negative	DLBCL-GCB	4	2	R-EPOCH	R-GDP, R-ESHAP, Pola + BR	N/A	Stopped sirolimus prior, low dose prednisone	No	No	None	PR at 1 month, progressive disease at 3 month
Lutt wak et. al. / Pt 1	69	M	DD KT, 1994	Tacrolimus	25	Negative	DLBCL – GCB	4B	4	R-da EPOCH	R-GDP	Pola+BR	Stopped CNI during bridging therapy, mean tac level during hospitalization 4.2 ng/mL	1	No	Febrile neutropenia w/bacterial infection	CR at 1 month, relapse at 3 month
Lutt wak et. al. / Pt 2	50	F	DDKT, 2011	Tacrolimus	5	Negative	DLBCL – GCB	4	4	R-CHOP	R-ICE + ASCT	Gemcitabine	Stopped CNI during bridging therapy, mean tac level during hospitalization 4.1 ng/mL	2	No	Prolonged neutropenia	CR at 1 month, sustained at 3 month
Lutt wak et. al. / Pt 3	66	M	DDLT, 2011	Tacrolimus	8	Negative	DLBC L-non GCB	3	4	R-CHOP	ICE	30 Gy radiotherapy	Stopped CNI during bridging therapy, mean tac level during hospitalization 3.3 ng/mL	1	No	AKI	PR at 1 month, sustained at 3 month

Abbreviations: DDKT, deceased donor kidney transplant; MMF, mycophenolate mofetil; EBV, Epstein Barr virus; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B-cell; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone; R-ICE, Rituximab, ifosfamide, carboplatin, and etoposide; R-DHAX, Rituximab, dexamethasone, cytarabine, and oxaliplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; R-GEM-Ox, rituximab, gemcitabine, oxaliplatin; GDP, gemcitabine, carboplatin and dexamethasone; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; Pola+BR, polatuzumab vedotin, bendamustine, rituximab; R-daEPOCH, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; ASCT, autologous stem cell transplantation; CNI, calcineurin inhibitor; AKI, acute kidney injury; RRT, renal replacement therapy; FUO, fever of unknown origin; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; CR, complete response; PR partial response